Brincidofovir

Brincidofovir is a prodrug form of the antiviral and acyclic nucleoside phosphonate cidofovir (Cay-13113). Brincidofovir is converted to cidofovir in MRC-5 human lung fibroblasts. It inhibits CMV, herpes simplex virus 1 (HSV-1), HSV-2, cowpox, and vaccinia virus replication in plaque reduction assays (EC50s = 0.0009, 0.06, 0.08, 0.6, and ~1 µM, respectively). Brincidofovir decreases mortality in mouse models of cowpox or vaccinia virus infections when administered at doses of 6.7 or 5 mg/kg, respectively. Formulations containing brincidofovir have been used in the treatment of smallpox disease.Formal Name: P-[[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-phosphonic acid, mono[3-(hexadecyloxy)propyl] ester. CAS Number: 444805-28-1. Synonyms: hexadecyloxypropyl-CDV, 1-O-hexadecyloxypropyl Cidofovir, CMX001, HDP-CDV, HDP (S)-HPMPC. Molecular Formula: C27H52N3O7P. Formula Weight: 561.7. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: Ethanol: soluble. lambdamax: 285 nm. SMILES: O=P(OCCCOCCCCCCCCCCCCCCCC)(O)CO[C@H](CO)CN1C(N=C(C=C1)N)=O. InChi Code: InChI=1S/C27H52N3O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-35-20-16-21-37-38(33,34)24-36-25(23-31)22-30-18-17-26(28)29-27(30)32/h17-18,25,31H,2-16,19-24H2,1H3,(H,33,34)(H2,28,29,32)/t25-/m0/s1. InChi Key: WXJFKKQWPMNTIM-VWLOTQADSA-N.